Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients.

30 May 2020

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.

29 May 2020

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma.

20 May 2020

Scientists find gene signature for poor response to standard therapy in rare uterine cancer

Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.

22 Apr 2020

Drug improves effectiveness of chemotherapy in ovarian cancer patients

An international research team, led by scientists from Mater Research - The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

16 Apr 2020

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Preclinical trials indicate that a drug candidate called OxaliTex can stop the growth of cancer cells completely. OxaliTex appears to be more potent than many other common chemotherapy drugs, with less toxicity and less rapidly counteracted by mechanisms of drug resistance. The study was reported in the journal Proceedings of the National Academy of Sciences in March 2020.

16 Mar 2020

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer.

21 Feb 2020

NCCN ORP plans to support phase II randomized trial for lung cancer patients

The National Comprehensive Cancer Network Oncology Research Program today announced plans to support a phase II randomized trial for lung cancer patients.

28 Oct 2019

Version of an antibiotic drug extends survival in mice with lethal pediatric brain tumors

Versions of an antibiotic drug called DON first isolated from soil bacteria more than 60 years ago have shown promising signs of extending survival in mice models of especially lethal pediatric brain tumors marked by the high expression of a cancer-causing gene known as the MYC oncogene, according to results of two studies from researchers at the Johns Hopkins Kimmel Cancer Center.

23 Sep 2019

Study links FAK protein to chemotherapy resistance in ovarian cancer

Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance and mortality remain high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer.

3 Sep 2019

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, “Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?”

27 Aug 2019

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Researchers at the Bellvitge Biomedical Research Institute, with the participation of collaborators from the Baylor College of Medicine and the University Institute of Oncology of Asturias, publish today in Cancer Research a study where they relate the high number of copies of a chromosomal region with the appearance of resistance to a chemotherapeutic drug.

19 Jun 2019

Cause of cancer is 'written' in our DNA as unique 'fingerprints'

Scientists have discovered that the cause of cancer is “written” within the DNA of tumors, a finding that could help doctors to decide on the best treatment for a patient.

16 Apr 2019

IASLC 2019 Small Cell Lung Cancer Meeting focuses on immunotherapy and patient perspective

While non-small cell lung cancer is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly.

29 Mar 2019

New combination treatment shows promise for common brain tumor in children

A new combination treatment aimed at resistant and recurrent low-grade gliomas slowed tumor growth and killed tumor cells in laboratory and mouse models.

22 Mar 2019

Clinigen, Accord Healthcare extend exclusive European clinical trial supply agreement

Clinigen Group plc, the global pharmaceutical and services company, announces that its Clinical Trial Service business has extended its exclusive European clinical trial supply agreement with Accord Healthcare. Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.

From Clinigen Group 11 Jan 2019

Aggressive prostate cancer linked to hereditary breast cancer, confirms study

Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others.

10 Jan 2019

Two genomic tests help identify most effective treatment for breast cancer patients

New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.

14 Nov 2018

U.S. Department of Defense grants 'Impact Award' to explore therapeutic options against advanced prostate cancer

The U.S. Department of Defense has granted the "Impact Award" to explore new therapeutic options against advanced prostate cancer - scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center, led by David Olmos, the Prostate Cancer Translational Research Group of the Vall d'Hebron Institute of Oncology, led by Joaquín Mateo, and the Genetics and Solid Tumors Laboratory of the University of Washington, led by Colin Pritchard.

7 Nov 2018

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

22 Oct 2018